课题基金 / 基金详情

CLINICAL TRIAL: ABT-751 COMBINED WITH DEXAMETHASONE, PEG-ASPARAGINASE, AND DOXOR

CLINICAL TRIAL: ABT-751 COMBINED WITH DEXAMETHASONE, PEG-ASPARAGINASE, AND DOXOR
临床试验:ABT-751 与地塞米松、PEG-天冬酰胺酶和 DOXOR 组合
批准号:
7982162
负责人:
Paul Samuel Gaynon
金额:
$0.12万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-12-01 至 2009-11-30

项目摘要

项目成果

Paul Samuel Gaynon的其他基金

相关文献

中文摘要
翻译
这个子项目是众多研究子项目之一
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This protocol is part of an investigator initiated IND (74,247) with the FDA for the investigational drug ABT-751. The protocol has been developed by the Therapeutic Advances in Childhood Leukemia (TACL) consortium in which the Operations Center is located at CHLA and the medical director is Dr. Paul Gaynon. TACL s mission is to develop protocols using new drugs in which provide an improvement upon the historical remission rate of 40% for patient treated with multiple relapsed ALL. ABT-751 drug is provided for use in this protocol by Abbott Laboratories. This is a multi-center phase I/II study whose primary objectives are 1) to establish in relapsed pediatric ALL patients a maximum tolerated dose (MTD) of ABT-751 in the context of a re-induction regimen that also includes dexamethasone, PEG-asparaginase, and doxorubicin, and 2) to determine whether there is evidence that ABT-751 will improve re-induction success rate in this context. The study will be performed in two parts. In Part 1, patients will be treated at one of a series of doses of ABT-751 according to a standard dose escalation design in order to establish the MTD. In Part 2, the 6 patients treated at the MTD in Part 1 will serve as the first stage of a multistage Phase II design, which will be used to evaluate the efficacy of this re-induction regimen.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CHILDRENS CANCER GROUP
CHILDRENS CANCER GROUP
CHILDRENS CANCER GROUP